Protocol Single compound
Semaglutide
GLP-1 agonist
Long-acting GLP-1 receptor agonist with extensive clinical literature on appetite and glycemic regulation.
Compare side by side →Compared with:Semaglutide vs TirzepatideSemaglutide vs Retatrutide
Protocol card · research reference
- Starting dose
- 0.25 mg
- Studied range
- 0.25–2.4 mg
- Frequency
- Once weekly
- Route
- Subcutaneous
- Cycle
- Ongoing, titrated every 4 weeks
Titration schedule
- 01Weeks 1–40.25 mg
- 02Weeks 5–80.5 mg
- 03Weeks 9–121.0 mg
- 04Weeks 13–161.7 mg
- 05Weeks 17+2.4 mg
Reconstitution reference
Storage: Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Semaglutide
Once weekly · units to draw on a U-100 syringe for a 0.25 mg dose.
| Vial | BAC water | mg/mL | Draw | Doses |
|---|---|---|---|---|
| 3 mg | 1 mL | 3 | 8.3 u | 12 |
| 3 mg | 2 mL | 1.5 | 16.7 u | 12 |
| 3 mg | 3 mL | 1 | 25 u | 12 |
| 5 mg | 1 mL | 5 | 5 u | 20 |
| 5 mg | 2 mL | 2.5 | 10 u | 20 |
| 5 mg | 3 mL | 1.67 | 15 u | 20 |
| 10 mg | 1 mL | 10 | 2.5 u | 40 |
| 10 mg | 2 mL | 5 | 5 u | 40 |
| 10 mg | 3 mL | 3.33 | 7.5 u | 40 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Semaglutide is a GLP-1 receptor agonist modified with a fatty-acid side chain that binds albumin, giving it a roughly week-long half-life. GLP-1 receptor activation increases glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and acts on brain appetite centres.
02
Observed research endpoints
- STEP 1 (adults with obesity, no diabetes): mean body-weight change of −14.9% vs −2.4% with placebo at week 68.
- SUSTAIN-6 (type 2 diabetes): major cardiovascular events in 6.6% vs 8.9% with placebo (hazard ratio 0.74).
- SELECT (cardiovascular disease + overweight, no diabetes): primary cardiovascular events in 6.5% vs 8.0% (hazard ratio 0.80).
03
Regulatory & safety context
- FDA-approved (as Ozempic, Wegovy and Rybelsus) for specific indications; research-grade material is not an approved product.
- Gastrointestinal effects were the most common adverse events; in SELECT, 16.6% stopped treatment for adverse events vs 8.2% on placebo.
- SUSTAIN-6 reported more diabetic retinopathy complications in the semaglutide group.
04
Citations
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.2021-03Phase 3 randomized controlled trialRead paper ↗
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.2016-11Cardiovascular outcomes RCTRead paper ↗
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.2023-12Cardiovascular outcomes RCTRead paper ↗
Keep exploring
Related compounds
Found in these stacks & blends
Head-to-head articles
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon